Peng Hou

7.4k total citations
177 papers, 5.7k citations indexed

About

Peng Hou is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, Peng Hou has authored 177 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Molecular Biology, 40 papers in Endocrinology, Diabetes and Metabolism and 38 papers in Oncology. Recurrent topics in Peng Hou's work include Epigenetics and DNA Methylation (36 papers), Thyroid Cancer Diagnosis and Treatment (31 papers) and RNA modifications and cancer (30 papers). Peng Hou is often cited by papers focused on Epigenetics and DNA Methylation (36 papers), Thyroid Cancer Diagnosis and Treatment (31 papers) and RNA modifications and cancer (30 papers). Peng Hou collaborates with scholars based in China, United States and United Kingdom. Peng Hou's co-authors include Meiju Ji, Mingzhao Xing, Qi Yang, Yiping Qu, Bingyin Shi, Haixia Guan, Dingxie Liu, Siwen Dang, Fang Sui and Vasily Vasko and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nano Letters and ACS Nano.

In The Last Decade

Peng Hou

173 papers receiving 5.6k citations

Peers

Countries citing papers authored by Peng Hou

Since Specialization

Citations

This map shows the geographic impact of Peng Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peng Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peng Hou more than expected).

Fields of papers citing papers by Peng Hou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peng Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peng Hou. The network helps show where Peng Hou may publish in the future.

Co-authorship network of co-authors of Peng Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Peng Hou. A scholar is included among the top collaborators of Peng Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peng Hou. Peng Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single-cell RNA sequencing integrated with bulk RNA sequencing analysis of clock circadian regulator with prognostic and immune microenvironment in thyroid cancer 2025 ·Translational Oncology ·Zhen Shen, (unknown), Xinxin Xu, (unknown), Shuting He, (unknown), (unknown), Peng Hou, Fang Sui	1
2	Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers 2025 ·Journal of Experimental & Clinical Cancer Research ·(unknown), (unknown), Simeng Wang, (unknown), (unknown), Jiaxin Liu, Pu Chen, Jianling Wang, Yuchen Zhang, Chengxue Dang, Peng Hou	5
3	USP44 inactivation accelerates the progression of thyroid cancer by inducing ubiquitylation and degradation of p21 2024 ·International Journal of Biological Sciences ·Yan Liu, (unknown), (unknown), (unknown), (unknown), Peng Hou, Wei Yu, Meiju Ji	1
4	Engineering PD-L1 targeted liposomal canagliflozin achieves multimodal synergistic cancer therapy 2024 ·Chemical Engineering Journal ·(unknown), (unknown), Quan Chen, Jiahua Guo, (unknown), (unknown), Meiju Ji, Yangyang Cheng, Peng Hou	5
5	Glucagon-modified Liposomes Delivering Thyroid Hormone for Anti-obesity Therapy 2023 ·Archives of Medical Research ·(unknown), Xinrui Zhou, Chao Feng, Wenfang Zheng, (unknown), Xiaozhi Zhang, Peng Hou	4
6	Hypoxia switches TET1 from being tumor-suppressive to oncogenic 2023 ·Oncogene ·Qi Yang, Hui Dang, Jiaxin Liu, Xingye Wang, Jingyuan Wang, (unknown), Meiju Ji, Mingzhao Xing, Peng Hou	13
7	STAG2 inactivation reprograms glutamine metabolism of BRAF-mutant thyroid cancer cells 2023 ·Cell Death and Disease ·Xinru Li, Yan Liu, Juan Liu, Qiang Wei, Jingjing Ma, (unknown), Pu Chen, (unknown), Peng Hou, Meiju Ji	4
8	Dipeptidyl Peptidase-4 Stabilizes Integrin α4β1 Complex to Promote Thyroid Cancer Cell Metastasis by Activating Transforming Growth Factor-Beta Signaling Pathway 2022 ·Thyroid ·Qingyuan He, Hongxin Cao, (unknown), Pu Chen, Na Wang, (unknown), Rongrong Cui, Peng Hou, Xiaozhi Zhang, Meiju Ji	15
9	GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to paclitaxel by forming a vicious cycle with IGF1/IGF1R signaling pathway 2022 ·Cell Death and Disease ·(unknown), (unknown), Jianling Wang, Hongxin Cao, Peng Feng, Siyu Wu, Na Wang, Chengxue Dang, Peng Hou, Peng Xia	4
10	Revisiting potential value of antitumor drugs in the treatment of COVID-19 2022 ·Cell & Bioscience ·Wenfang Zheng, (unknown), Shumei Lin, Peng Hou	2
11	Identification of a germline CSPG4 variation in a family with neurofibromatosis type 1-like phenotype 2021 ·Cell Death and Disease ·(unknown), Yiping Qu, (unknown), (unknown), Zhèn Yáng, Meiju Ji, Peng Hou	2
12	The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53 2021 ·Cell Death and Differentiation ·Xi Su, Chao Feng, Simeng Wang, Liang Shi, Qingqing Gu, Haihong Zhang, (unknown), (unknown), Qiang Wei, Meiju Ji, Peng Hou	40
13	Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment 2021 ·Journal of Nanobiotechnology ·Simeng Wang, Xinrui Zhou, (unknown), (unknown), Lihong Chen, Chao Feng, Chen Huang, Qi Yang, Meiju Ji, Peng Hou	36
14	ZNF677 Suppresses Akt Phosphorylation and Tumorigenesis in Thyroid Cancer 2018 ·Cancer Research ·Yujun Li, Qi Yang, Haixia Guan, Bingyin Shi, Meiju Ji, Peng Hou	53
15	Gender-related differences in the association between concomitant amplification of AIB1 and HER2 and clinical outcomes in glioma patients 2018 ·Pathology - Research and Practice ·Fang Sui, (unknown), Xi Su, Pu Chen, Peng Hou, Bingyin Shi, Qi Yang	10
16	TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways 2018 ·Thyroid ·Na Wang, (unknown), Wei Jing, Jun Pu, Rui Liu, Qi Yang, Haixia Guan, Bingyin Shi, Peng Hou, Meiju Ji	40
17	c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer 2018 ·Thyroid ·Yiqi Li, Xinru Li, Jun Pu, Qi Yang, Haixia Guan, Meiju Ji, Bingyin Shi, Mingwei Chen, Peng Hou	23
18	Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling Pathways 2009 ·The Journal of Clinical Endocrinology & Metabolism ·Peng Hou, Ermal Bojdani, Mingzhao Xing	112
19	Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin 2009 ·Cancer Research ·Dingxie Liu, Peng Hou, Zhi Liu, Guojun Wu, Mingzhao Xing	75
20	Hypermethylation of the DNA mismatch repair gene hMLH1 and Its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer 2008 ·Cancer ·Haixia Guan, Meiju Ji, Peng Hou, Zhi Liu, Cuifang Wang, Zhongyan Shan, Weiping Teng, Mingzhao Xing	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact